The antiviral remdesivir has been shown to decrease the length of hospital stay in
coronavirus disease 2019 (COVID‐19) patients requiring supplemental oxygen. However …

Background Remdesivir is the only antiviral agent approved for the treatment of hospitalized
coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies …

Aim To evaluate the association of remdesivir use and the survival of hospitalized patients
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …

Remdesivir is one of the most attractive options for patients with hypoxemic respiratory
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …

Rationale Remdesivir and dexamethasone reduced the severity of COVID-19 in clinical
trials. However, their individual or combined effectiveness in clinical practice remains …

Background Studies on the antiviral effects of remdesivir have shown conflicting results.
SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Remdesivir treatment, like most antiviral drugs, is likely to be most effective
when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of SARS-CoV-2. Methods This was a retrospective comparative …

Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …